The stock's rise snapped a three-day losing streak.

New insights from 30,026 people across 13 markets show the global scale of poor sleep and its impact on health, work, and relationships7 out of 10 employed respondents have called in sick at least onc ...

ResMed (NYSE:RMD) has had a rough month with its share price down 7.5%. However, stock prices are usually driven by ...

Shares of ResMed Inc. RMD slipped 1.03% to $230.58 Tuesday, on what proved to be an all-around great trading session for the ...

Principal Financial Group Inc. trimmed its stake in ResMed Inc. (NYSE:RMD – Free Report) by 0.5% during the 4th quarter, Holdings Channel reports. The firm owned 185,788 shares of the medical ...

Equities researchers at Zacks Research raised their Q3 2025 earnings per share estimates for ResMed in a report issued on Wednesday, February 19th. Zacks Research analyst R. Department now anticipates ...

Brett Fishbin; Analyst; KeyBanc Capital Markets Inc. Welcome to the Q2 fiscal-year 2025 ResMed earnings conference call. My name is Matt and I'll be your operator for today's call. (Operator ...

The global high flow nasal cannula market is set to experience a notable downturn over the next decade, with forecasts indicating a decline from USD 1,369.3 million in 2024 to USD 1,063.0 million by ...

ResMed Inc. (NYSE:RMD) Q2 2025 Earnings Call Transcript January 30, 2025 ResMed Inc. beats earnings expectations. Reported EPS is $2.43, expectations were $2.32. Operator: Welcome to the Q2 Fiscal ...

ResMed’s strong demand for AirSense 11 boosts its earnings outlook. Learn why RMD stock is undervalued with growth opportunities in the sleep apnea market.

ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended December 31, 2024. Revenue increased by 10% to $1.3 billion; up 10% on a constant currency basis Gross margin ...